Cell Processing

The Center for Breakthrough Medicines features customizable manufacturing suites staffed by industry experts. Workflows and equipment configurations are aligned to develop and produce innovative advanced therapies. Flexibility is built into each process to meet client-specific needs.

For autologous products, we employ the most sophisticated scheduling, supply chain and inventory control systems aligned with in-process testing, quality control, and lot release programs to overcome manufacturing challenges.

For allogeneic products, well-characterized cell banks may be scaled-up with adherent systems or single-use bioreactors to meet the clinical and commercial demand for cell products at significant scale.

Our manufacturing capabilities include but are not limited to the following:

  • Autologous and Allogeneic CAR-T cells
  • Tumor infiltrating lymphocytes (TILs)
  • Enhanced T-Cell receptors (TCRs)
  • Stem cell therapies and induced pluripotent stem cells (iPSCs) 
  • Tumor cell vaccines
  • Dendritic cell and NK cell adoptive Immunotherapies